Prpthena/Roche deal for a-syn targeting a-syn for PDThey

They cut a deal in 2013 for Prothena's monoclonal antibody targeting a-syn clumps around the peripherals of the neurons. Several Phase 2's later, with some success, they are in a 3 stage Phase 2 (PASADENA) [complete]Phase 2B (PADOVA)[ongoing] to be followed by an open label extension. The MOA is preventing oligomer groups from passing between neurons, claim they can slow or stop progression of Parkinson's disease.
The deal is up to 600 million, including up front payments and near term clinical milestone payments totalling 45 million, as well as 30% of US profits and up to double digit royalties on ex- US sales.
That was a pretty good deal IMO for a P1 asset at the time.
Prothena was cleaved off from the giant Irish biotech Elan, before Elan was taken over by the US generic company Perrigo. Prothena was well funded, and was in a position to share development costs with Roche. I think it is Dale Shenk ex-Elan now at Prothena.
The current trial group is early stage.
To me ATH 434 should be able to demonstrate superiority over an MOA like that. First they need to beat that placebo.
The Roche trials ongoing now have an exclusion list as long as your arm, including MSA and L-Dopa. If you want to read more google " Roche and Prothena enter into worldwide collaboration to co-develop and co promote antibodies for treatment of parkinson's"